At a glance
- Originator Yamanouchi
- Developer Kissei Pharmaceutical; Yamanouchi
- Class Antiemetics
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome; Nausea and vomiting
Most Recent Events
- 24 Aug 1999 Discontinued-II for Emesis in Japan (Injection)
- 24 Aug 1999 Discontinued-II for Emesis in Japan (PO)
- 24 Aug 1999 Discontinued-II for Irritable bowel syndrome in Japan (PO)